Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215707 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses
A Phase 1 study, sponsored by Sanaria.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02215707 is a Phase 1 study that has completed, run by Sanaria. The registered enrollment target is 67 participants.
The verdict
NCT02215707, a Phase 1 study, has completed, sponsored by Sanaria.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is an open-label evaluation of the safety, tolerability immunogenicity and efficacy of the PfSPZ Vaccine administered by Direct Venous Inoculation (DVI) in healthy, malaria-naïve subjects. There will be 3 groups and a total of 69 subjects (45 immunized subjects and 24 infectivity controls).
Interventions
- BIOLOGICAL PfSPZ Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215707
The ClinicalTrials.gov registry entry for NCT02215707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanaria, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PfSPZ Vaccine is the first listed.
NCT02215707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02215707 about?
NCT02215707 is a clinical study titled "A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses". This is an open-label evaluation of the safety, tolerability immunogenicity and efficacy of the PfSPZ Vaccine administered by Direct Venous Inoculation (DVI) in healthy, malaria-naïve subjects. There will be 3 groups and a total of 69 subjects (45 immunized subjects and 24 infectivity controls).
What is the current status of trial NCT02215707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2014-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02215707?
The interventions under investigation include: PfSPZ Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02215707?
This trial is sponsored by Sanaria, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.